Funded Tech Companies
DeuterOncology
DeuterOncology, operating out of Liege, received equity investments from Newton Biocapital, Noshaq and InvestSud.
Company Overview
Company Name
DeuterOncology
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
Clos Chanmurly 13
Liege, 4000
Belgium
Liege, 4000
Belgium
Phone
Undisclosed
Website
Email Address
Company Background Information
Overview
DeuterOncology NV was founded in September 2020 by? Dr Timothy Perera and is based in Liege in Belgium. The company generated pre-clinical validation of DO-2, a novel, highly selective, brain penetrant deuterated MET kinase and RAS pathway inhibitor. Timothy Perera was the originator of the initial idea for the use of deuteration as a means to modulate metabolic properties of the parent drug and remains a strong champion of this exciting new molecule. The molecule was in-licensed (worldwide rights outside of greater China) from OCTIMET Oncology NV and originally licensed from Janssen Pharmaceutica in 2017.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
1/19/2023
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Timothy Perera
Chief Financial Officer
Tomas Dyck
Chief Medical Officer
Jaap Verweij
Company Investors
Browse more funded tech companies:
Share this article
About Our Venture Capital Database
This tech company profile is powered by VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs